Credit rating agency, CARE has reaffirmed ‘D’ rating to Parabolic Drugs’ long term bank facilities worth Rs 696.60 crore which was enhanced from Rs 472.93 crore. The rating agency has also reaffirmed ‘D’ rating to the company’s short-term bank facilities worth Rs 108.68 crore which was reduced from Rs 317.68 crore. The rating continues to take into account the ongoing delays in debt servicing on account of the tight liquidity position of the company.
Parabolic Drugs (PDL) has commenced its commercial operations in 1998 with contract manufacturing of APIs and API intermediates for sales in India and abroad (including regulated markets). PDL presently has four facilities comprising of three manufacturing plants, viz, Derabassi and Chachrauli (both Punjab) and Panchkula and an R&D centre at Barwala (both Haryana).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: